Assessment of in vitro inhibitory effects of novel anti MRSA benzoquinolizine fluoroquinolone WCK 771 (levonadifloxacin) and its metabolite on human liver cytochrome P450 enzymes

References

• Bayer HealthCare Pharmaceuticals Inc. (2010). Highlights of prescribing Information: AVELOX (moxifloxacin hydrochloride) Film coated tablet, injection, solution for IV use. Available from: www.accessdata.fda.gov/drugsatfda_docs/label
   Google Scholar
• Bayer HealthCare Pharmaceuticals Inc. (2016). Highlights of prescribing Information: CIPRO (ciprofloxacin hydrochloride) Tablet for oral use, oral suspension. Available from: www.accessdata.fda.gov/drugsatfda_docs/label
   Google Scholar
• Bhagwat S, Mundkur L, Gupte S, et al. (2006). The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase. Antimicrobial Agents and Chemotherapy 50:3568–79.
   PubMed Web of Science ®Google Scholar
• Bhagwat SS, Nandanwar M, Kansagara A, et al. (2019). Levonadifloxacin, a novel broad-spectrum anti-MRSA benzoquinolizine quinolone agent: review of current evidence. Drug Design, Development and Therapy 13:4351–65.
   PubMed Web of Science ®Google Scholar
• Chugh R, Lakdavala F, Bhatia A. (2016). Safety and pharmacokinetics of multiple ascending doses of WCK 771 and WCK 2349. In: Abstracts of the 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); Amsterdam, Netherlands. Abstract P1268. Basel, Switzerland: European Society of Clinical Microbiology and Infectious Diseases.
   Google Scholar
• Chugh R, Lakdavla F, Bhagwat S, et al. (2015). Food effect and absolute bioavailability study of WCK 2349 and WCK 771 in healthy adult human volunteers in U.S. In: Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); San Diego, CA. Abstract A-039. Washington, DC: American Society for Microbiology.
   Google Scholar
• Dierks EA, Stams KR, Lim HK, et al. (2001). A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab. Dispos 29:23–9.
   PubMed Web of Science ®Google Scholar
• Fish ND. (2001). Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy 21:253S–72S.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. (1997). Role of cytochrome P450 enzymes in drug-drug interactions. Adv. Pharmacol 43:7–35.
   PubMedGoogle Scholar
• Hu X, Huang W, Yang Y. (2015). Cytochrome P450 isoenzymes in rat and human liver microsomes associate with the metabolism of total coumarins in Fructus Cnidii. Eur J Drug Metab Pharmacokinet 40:373–7.
   PubMed Web of Science ®Google Scholar
• Ivaturi V, Niu J, Chugh R, et al. (2015). Population pharmacokinetics of levonadifloxacin administered as WCK 2349, a novel oral benzoquinolizine quinolone prodrug. In: Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); San Diego, CA. Abstract A-033. Washington, DC: American Society for Microbiology.
   Google Scholar
• Janssen Ortho LLC. 2008: Highlights of prescribing Information: LEVAQUIN (Levofloxacin) Tablets, oral solution, injection for intravenous use. Available from: www.accessdata.fda.gov/drugsatfda_docs/label
   Google Scholar
• Kenworthy KE, Bloomer JC, Clarke SE, Houston JB. (1999). CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48:716–27.
   PubMed Web of Science ®Google Scholar
• Kim MJ, Kim H, Cha IJ, et al. (2005). Highthroughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom 19:2651–8.
   PubMed Web of Science ®Google Scholar
• Kim SK, Novak RF. (2007). The role of intracellular signaling in insulinmediated regulation of drug metabolizing enzyme gene and protein expression. Pharmacol. Ther 113:88–120.
   PubMed Web of Science ®Google Scholar
• Lee KS, Kim SK. (2013). Direct and metabolism-dependent cytochrome P450 inhibition assays for evaluating drug–drug interactions. J Appl Toxicol 33:100–8.
   PubMed Web of Science ®Google Scholar
• Leveque D, Jehl F. (2009). Molecular determinants of fluoroquinolone antibacterial agents pharmacokinetics. Curr Clin Pharmacol 4:191–7.
   PubMedGoogle Scholar
• Liu T, Qian G, Wang W, Zhang Y. (2015). Molecular docking to understand the metabolic behavior of GNF-351 by CYP3A4 and its potential drug-drug interaction with ketoconazole. Eur J Drug Metab Pharmacokinet 40:235–8.
   PubMed Web of Science ®Google Scholar
• Mason JW, Chugh R, Lakdavala F, Bhatia A. (2016). Electrocardiographic effects of WCK 2349. In: Abstracts of the 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); Amsterdam, Netherlands. Abstract P1269. Basel, Switzerland: European Society of Clinical Microbiology and Infectious Diseases.
   Google Scholar
• Melinta Therapeutics. (2017). Highlights of prescribing Information: BAXDELA (Delafloxacin) Tablet for oral use, oral suspension, injection for intravenous use. Available from: www.accessdata.fda.gov/drugsatfda_docs/label
   Google Scholar
• Niu J, Ivaturi V, Niu J, et al. (2015). Pharmacokinetics of levonadifloxacin administered as intravenous WCK 771 and oral WCK 2349 in healthy Indian male adults. In: Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA. Abstract A-032. Washington, DC: American Society for Microbiology.
   Google Scholar
• Peterson LR. (2001). Quinolone molecular structure-activity relationships: what we have learned about improving antimicrobial activity. Clin Infect Dis 33:S180–S6.
   PubMed Web of Science ®Google Scholar
• Preston RA, Chugh R, Mastim M, Bhatia A. (2016). Single-center evaluation of the pharmacokinetics and safety of the novel fluoroquinolone WCK 2349 in hepatic impairment. In: Abstracts of the 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); Amsterdam, Netherlands. Abstract P1270. Basel, Switzerland: European Society of Clinical Microbiology and Infectious Diseases.
   Google Scholar
• Rodvold KA, Gotfried MH, Chugh R, et al. (2018). Intrapulmonary pharmacokinetics of levonadifloxacin following oral administration of alalevonadifloxacin to healthy adult subjects. Antimicrob Agents Chemother 62:e02297–17.
   PubMed Web of Science ®Google Scholar
• Shiu J, Ting G, Kiang TK. (2019). Clinical pharmacokinetics and pharmacodynamics of delafloxacin. Eur J Drug Metab Pharmacokinet 44:305–17.
   PubMed Web of Science ®Google Scholar
• Walsky RL, Obach RS. (2004). Validated assays for human cytochrome p450 activities. Drug Metab Dispos 32:647–60.
   PubMed Web of Science ®Google Scholar
• Yeole RD, Rane VP, Ahirrao VK, et al. (2019). Identification of metabolites of novel anti‐MRSA fluoroquinolone WCK 771 in mouse, rat, rabbit, dog, monkey and human urine using liquid chromatography tandem mass Spectrometry. Biomed Chromatogr 33:e4532.
   PubMed Web of Science ®Google Scholar
• Zhang J-W, Liu Y, Cheng J, et al. (2007). Inhibition of human liver cytochrome P450 by star fruit juice. J Pharm Pharm Sci 10:496–503.
   PubMed Web of Science ®Google Scholar
• Zhang H, Ya G, Rui H. (2017). Inhibitory effects of triptolide on human liver cytochrome P450 enzymes and p-glycoprotein. Eur J Drug Metab Pharmacokinet 42:89–98.
   PubMed Web of Science ®Google Scholar
• Zhou S, Chan E, Li SC, Huang M, et al. (2004). Predicting pharmacokinetic herb-drug interactions. Drug Metabol Drug Interact 20:143–58.
   PubMedGoogle Scholar
• Zhou S, Yung CS, Cher GB, et al. (2005). Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44:279–304.
   PubMed Web of Science ®Google Scholar